ClinicalTrials.gg
Active, not recruitingNCT07321951Updated Jun 4, 2026

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of SHR-1819 Injection and SHR-1819 Injection Blank Preparation in Moderate-to-severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
4th of 14
201 · median 159
Started
2026
with 3 others
Phase 2
6 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by enrollment, is one of 4 that started in 2026, is one of 6 in phase 2, and was the 13th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of signing the , the subjects are ≥18 years old and ≤75 years old, male or female.
  2. The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
  3. Topical emollients are applied at a stable dose twice daily for at least 7 days before the first dose in the run-in phase and continued for the duration of the study.
  4. Have atopic dermatitis at the time of screening and have an investigator-assessed history of atopic dermatitis for at least 1 year before screening.
  5. Have moderate to severe atopic dermatitis during the screening period and on the day of the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
  2. A history of spring keratoconjunctivitis and/or atopic keratoconjunctivitis within 6 months prior to screening.
  3. Has or has a history of malignancy.
  4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
  5. to the study drug or any ingredient in the study drug.
  6. Females who are pregnant or lactating.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    SHR-1819 Injection Group with Dose 1

    Drug: SHR-1819 Injection · Drug: SHR-1819 Injection Blank Preparation

  • Experimental
    SHR-1819 Injection Group with Dose 2

    Drug: SHR-1819 Injection · Drug: SHR-1819 Injection Blank Preparation

  • Experimental
    SHR-1819 Injection Group with Dose 3

    Drug: SHR-1819 Injection · Drug: SHR-1819 Injection Blank Preparation

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of participants who achieved EASI-75 (≥75% decrease in the score on the Eczema Area and Severity Index (EASI) from the baseline).

    Eczema Area and Severity Index score using the Eczema Area and Severity Index scale.

    Time frame: Week 24.

Secondary outcomes

  1. The proportion of participants with a baseline daily Itch Numeric Rating Scale (I-NRS) score of ≤4 per week.

    The Itch Numeric Rating Scale score using the Itch Numeric Rating Scale.

    Time frame: Week 24.

  2. Adverse events (AEs).

    Time frame: About 42 weeks.

  3. The concentration of SHR-1819 in serum.

    Time frame: From week -16 to week -8, about every 4 weeks; From week 0 to week 32, about every 8 weeks.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 17 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2025
First posted
Jan 7, 2026
StartActual
Jan 9, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07321951
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 9, 2026
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drotokibart · SHR-1819

Start the discussion